The Latest Breaking News from Moderna

Ebola vaccine trials 'reason for hope' in DR Congo and beyond

Five months into the Ebola outbreak in the Democratic Republic of Congo, there is still no approved vaccine against the rare Bundibugyo strain that has now caused more than 4,000 deaths. But candidates currently undergoing trials give reason to hope, according to Emanuele Capobianco of Gavi, the global vaccine alliance.

Radio France Internationale · 9h ago

Stocks Settle Higher on Earnings Optimism

The S&P 500 Index ($SPX ) (SPY ) closed up by +0.59% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.83%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.51%. December E-mini S&P futures (ESZ26 ) rose +0.59%, and December E-mini...

Barchart · Oct 9

Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine Initiative

Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in playing MRNA shares at current levels.

Barchart · Oct 9

Unusual Options Activity in Microsoft Stock Is Already Paying Off (and 3 Other Stocks to Watch)

Microsoft's 14,875-contract bull call spread ($525/$600, Oct. 30) gained 3% in one day. For non-tech alternatives, Robinhood's $123/$128 call spread, Moderna's $195/$205 combo (already profitable), and ExxonMobil's $167.50/$172.50 spread offer varying risk/reward, though XOM's breakeven exceeds its analyst target price.

Barchart · Sep 25

Opinion: The First Personalized mRNA Cancer Vaccine Just Passed a Major Test: Now Comes the Hard Part

A late-stage trial found that a custom-built mRNA therapy added to immunotherapy reduced melanoma recurrence. An oncologist argues the result is a genuine milestone, but patients deserve clear answers on the size of the benefit, survival, cost, and access before the hype takes over.

Medical Daily · Sep 23

Moderna's Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson's drug

CI is pairing top AI and biotech minds on its board (plus an advisory role for OpenAI's Fidji Simo) as it tests models on a Novo Nordisk drug.

Fortune · Sep 21

This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%

Merck is beating the market year-to-date after a jump on positive Phase 3 data, while paying an annualized dividend of about $3.40 for a yield above 2.3%.

Barchart · Sep 16

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

MarketBeat · Sep 6

The FDA just approved this year’s Covid vaccines - here’s what you need to know about the shots

The vaccines are expected to roll out at hospitals and pharmacies in just days

The Independent UK · Aug 28

Updated COVID Shots Matched to the XFG Variant Reach Pharmacies While Federal Eligibility Guidance Remains Unsettled

FDA approved updated 2026-2027 COVID vaccines targeting XFG. Here is who qualifies, what insurance covers, and what guidance is still missing.

Medical Daily · Aug 28